Evidence map›Paper›PMID 39409156›Full record

ArticleInternational journal of molecular sciences2024

PD-L1

Giedrė Gurevičienė, Jurgita Matulionė, Lina Poškienė, Skaidrius Miliauskas, Marius Žemaitis

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giedrė GurevičienėDepartment of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
Jurgita MatulionėDepartment of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
Lina PoškienėDepartment of Pathology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
Skaidrius MiliauskasDepartment of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.ORCID 0009-0002-6130-0712
Marius ŽemaitisDepartment of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The non-canonical PD-L1 pathway revealed that programmed-death ligand 1 (PD-L1) expression in immune cells also plays a crucial role in immune response. Moreover, immune cell distribution in a tumour microenvironment (TME) is pivotal for tumour genesis. However, the results remain controversial and further research is needed. Distribution of PD-L1-positive (PD-L1

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungCD4-Positive T-LymphocytesForkhead Transcription FactorsInterleukin-17Lung NeoplasmsLymphocytes, Tumor-InfiltratingMacrophagesTumor MicroenvironmentAgedFemaleHumansMaleMiddle AgedNeoplasm StagingB7-H1 AntigenCD274 protein, humanForkhead Transcription FactorsFOXP3 protein, humanIL17A protein, humanInterleukin-17lymphocytesmacrophagesnon-small cell lung cancerprogrammed death-ligand 1tumour microenvironment

Identifiers

PMID39409156
PMCPMC11477418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.